DOI: https://doi.org/10.26641/2307-0404.2015.3.53687

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka, I. Selina, A. Usenko

Abstract


Aim of this study was to analyze molecular genetic and cytogenetic reasons for disease resistance to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) in patients with chronic myeloid leukemia (CML). Material and methods. A group of 32 CML patients with primary or acquired resistance to TKI treatment was investigated. Cytogenetic response was determined by conventional karyotyping with differential banding. Presence of BCR-ABL kinase domain mutations was investigated by direct sequencing. Results and discussion. The frequency of mutations was 37% (12 patients) with prevailing occurrence of mutations with low sensitivity to nilotinib – E255K/V; Т315I; F359V; Y253H. In 47% of the cases (15 patients) additional chromosome aberrations (ACA) were revealed which could also be the reason for TKI resistance in patients without BCR/ABL mutations. Patients with detected mutations of BCR/ABL gene were either switched to nilotinib or treated with increased dose of IM. Cytogenetic response was achieved in only 2 patients with mutations and in 12 patients without them. Frequency of blast crisis development did not differ significantly in both groups. Conclusions. Among the investigated patients with CML resistant to IM BCR/ABL gene mutations were detected in more than third of the cases whereas ACA were found in almost half of the group. Taking into account revealed prevalence of mutations not sensitive to the 2nd generation TKI nilotinib, investigation of mutational status has to be obligatory in all patients for whom treatment correction is considered. Presence of ACA should also be taken into account in patients requiring administration of the second line TKI since they can adversely influence expected treatment response as well. 


Keywords


chronic myeloid leukemia; kinase domain mutations of BCR-ABL gene; chromosome aberrations; imatinib; nilotinib

Full Text:

PDF

References


Andreyeva SV, Drozdova VD. [Guidelines for ana¬lysis of chromosome preparations in hematologic neoplasms]. Kyiv, 2007;44. Ukrainian. 2. Misiurin AV, Aksenova EV, Krutov AA, et al. [Mo¬lecular diagnostics of chronic myeloid leukemia]. Gematologia i transfuziologia. 2007;2:35-40. Russian. 3. Turkina AG, Khoroshko ND, Zaritskiy AY, et al. [Achievements in treatment of CML. Therapeutic prob-lems and ways of their solution, 2009 – 2012]. Vestnik ge¬matologii, 2009;V(2):44-45. Russian. 4. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(11):1018-29. 5. Khorrashad JS, Kelley TV, Szankasi P, et al. BCR-ABL1 compaund mutations in tyrosine kinase in-hibitor resistant CML: frequency and clonal relationship. Blood. 2013;121(3):489-98. 6. Soverini S, Hochhaus A, Nicolini FE, et al.BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European Leukemia Net. Blood. 2011;118(5):1208-215. 7. Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the mana-gement of cnronic myeloid leukemia: 1013. Blood. 2013;122(6):872-84. 8. Goldman JM. How I treat chronic myeloid leu-kemia in the imatinib era. Blood. 2007;110:2828-37. 9. O’Hare T, Walters DK, Stoffregen EP, et al. In vit-ro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500-05. 10. Мilojkovic D, Apperley J. Mechanisms of resis-tanяce to imatinib and second-generation tyrosine inhi¬bi-tors in chronic myeloid leukemia. Clin Cancer Res. 2009;15:7519-27. 11. Cortes JE, Kantarjian H, Shah NP, et al. Pona¬tinib in refractory Philadelphia chromosome-positive leukemias. N. Eng. J. Med. 2012;367(22):2075-88. 12. Parker WT, Lawrence RM, Ho M, et al. Sensitive detection of BCR-ABL1 mutations in patients with chro-nic myeloid leukemia after imatinib resistance is pre-dictive of outcome during subsequent therapy. J Clin On-col. 2011;29(32):4250-9. 13. Nicolini FE, Ibrahim AR, Soverini S, et al.The BCR-ABL T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510-6.


GOST Style Citations


1. Андреєва С.В. Стандарти аналізу препаратів хро¬мосом при неоплазіях кровотворення: метод. реко-ме¬н¬дації / С.В. Андреєва, В.Д. Дроздова. – К., 2007. – 44 с. 2. Молекулярная диагностика хронического мие¬ло¬лейкоза / А.В. Мисюрин, Е.В. Аксенова, А.А. Кру¬тов [и др.] // Гематология и трансфузиология. – 2007. – № 2. – C. 35-40. 3. Успехи в лечении больных ХМЛ. Проблемы тера¬пии и пути их решения 2009-2012 гг / А.Г. Тур-кина, Н.Д. Хорошко, А.Ю. Зарицкий [и др.] // Вестник гематологии. – 2009. – Т. 5, № 2. – C. 44-45. 4. Apperley J. F. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia / J.F. Ap¬perley // Lancet Oncol. – 2007. – Vol. 8, N 11. – P. 1018-1029. 5. BCR-ABL1 compaund mutations in tyrosine ki-nase inhibitor resistant CML: frequency and clonal re¬la-tion¬ship / J.S. Khorrashad, T.V. Kelley, P. Szankasi [et al.] // Blood. – 2013. – Vol. 121, N 3. – P. 489-498. 6. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European Leukemia Net / S. Soverini, A. Ho¬ch¬haus, F.E. Nicolini [et al.] // Blood. – 2011. – Vol. 118, N 5. – P. 1208-1215. 7. European Leukemia Net recommendations for the management of chronic myeloid leukemia: 1013 / M. Bac¬carani, M.W. Deininger, G. Rosti [et al.] // Blood. – 2013. – Vol. 122, N 6. – P. 872-884. 8. Goldman JM. How I treat chronic myeloid leuke-mia in the imatinib era / J.M. Goldman // Blood. – 2007. – Vol. 110. – P. 2828-2837. 9. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-re-sis¬tant Abl kinase domain mutants / T. O’Hare, D.K. Wal-ters, E.P. Stoffregen [ et al.] // Cancer Res. – 2005. – Vol. 65, N 11. – P. 4500-4505. 10. Milojkovic D. Mechanisms of resistance to ima-tinib and second-generation tyrosine inhibitors in chronic myeloid leukemia / D. Milojkovic, J. Apperley // Clin. Can¬cer Res. – 2009. – Vol. 15. – P. 7519-7527. 11. Ponatinib in refractory Philadelphia chromosome-positive leukemias / J.E. Cortes, H. Kantarjian, N.P. Shah [et al.] // N. Eng. J. Med. – 2012. – Vol. 367, N 22. – P. 2075-2088. 12. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent the-rapy / W.T. Parker, R.M. Lawrence, M. Ho [et al.] // J. Clin. Oncol. – 2011. – Vol. 29, N 32. – P. 4250-4259. 13. The BCR-ABL T315I mutation compromises sur-vival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis / F.E. Nicolini, A.R. Ibrahim, S. So-verini [et al.] // Haematologica. – 2013. – Vol. 98. – P. 1510-1516.




 

This work is licensed under a Creative Commons Attribution 4.0 International License